Specialty Hub Services/Patient Assistance Providers News Roundup


AscellaHealth, a global healthcare and specialty pharmacy (SP) solutions company announced a strategic partnership with 4Merit Connections, a dedicated provider of exceptional outsourced services to the UK government. This collaboration marks the formation of 4Merit Connections, a global joint venture aimed at delivering comprehensive services and solutions to governments and public organizations around the world. AscellaHealth services patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies.


Driven to transform and unify commercialization services for pharmaceutical brands entering or expanding into Europe, EVERSANA, a leading provider of commercialization services to the life sciences industry, has united seven leading organizations to form the Global Alliance for Pharma Solutions (GAPS). GAPS harnesses a robust international network and unique technologies to meet the strategic demands of the pharmaceutical and healthcare sectors worldwide. Combined with EVERSANA, the alliance boasts over 8,400 professionals across more than 55 nations. EVERSANA® is a leading independent provider of global services to the life sciences industry. 


Market-leading commercialization platform, Inizio, announced ‘Inizio Launch Elevate’, a connected suite of its best-in-class capabilities designed to accelerate and simplify product launches for global pharma and biotech companies. Inizio Launch Elevate combines deep market and patient insights, launch strategy expertise, and rigorous cross-functional execution to ensure relentless alignment throughout the product launch process. Successful launches are underpinned by evidence, data, technology, and stakeholder management to navigate the complexity involved in market launch activity. Inizio’s connected capabilities harness the power of its specialist commercialization platform to unlock, activate, and optimize the value of their clients’ innovations across each pivotal moment of their product launch journey. 


IntegriChain, delivering pharma’s only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, announced the appointment of Jeff Uccello as Senior Vice President and General Manager of Data Solutions. Uccello is a seasoned pharma data executive with more than 20 years of experience across a wide range of commercialization data and analytics and business leadership roles. He will lead IntegriChain’s resurging Data business, including the highly differentiated and industry-leading Channel Data solutions and the innovative Patient Access solutions as well as their integration into key ICyte Contracts & Pricing and Gross-to-Net workflows for modeling and decision-making.


IntegriChain also announced the close of an investment agreement whereby Nordic Capital has acquired the majority stake in IntegriChain.  IntegriChain’s integrated ICyte Platform helps pharma manufacturers connect the commercial, financial, and operational dimensions of drug commercialization, access, and profitability. Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in Healthcare and Pharma,  acquired the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.


Lumanity, a global strategic services partner, is realigning its strategic consulting capabilities to help clients more effectively create and demonstrate the value of assets throughout the development and commercialization lifecycle. Lumanity acquired Clarion, a Boston-based life science consultancy, in October 2022. Clarion is now rebranding under Lumanity. In addition, Lumanity is realigning its Commercial, Medical Affairs, and Clinical and Regulatory Strategy teams into a single global Strategy Consulting capability. With offices in North America, the United Kingdom, European Union, and Asia, and work conducted in over 50 countries, Lumanity works with nearly all of the top pharmaceutical companies and more than 100 biotech companies around the world. Every year, Lumanity supports over 50 payer submissions across 20+ countries, launch readiness and commercialization of over 80 brands and new indications.


Mercalis, an integrated life sciences commercialization partner that provides comprehensive solutions that span the entire healthcare value chain, announced an exclusive perpetual license to a portfolio of access and adherence technologies from OptimizeRx, a health technology company focused on bringing life sciences support to patients and providers. Core within this deal is a compilation of technologies that further expands the Mercalis catalog of eServices transactions including pharmacy eligibility, electronic real-time benefits investigation, electronic prior authorizations, medical eligibility, and financial acceptance screening. Mercalis is an integrated life sciences commercialization partner that provides comprehensive solutions that span the entire healthcare value chain.


Takeaway: AMI’s annual Specialty Hub Service Providers Report provides comprehensive business intelligence on more than 75 companies